The Bioabsorbables/Bioresorbables Center

Filter Your Results

 

News

 

Carag Begins European Marketing After CE Mark Approval for Bioresorbable Septal Occluder  

September 18, 2017 -- Carag AG announced that it has received European CE Mark approval for its Carag bioresorbable septal occluder (CBSO), allowing Carag to fully market the …

Abbott Will Stop Sales of Absorb Bioresorbable Vascular Scaffold System

September 8, 2017 -- Abbott Vascular announced that it will stop selling the first-generation Absorb bioresorbable vascular scaffold system and the Absorb GT1 bioresorbable va…

One-Year Data Presented From BIOFLOW-V Pivotal Trial of Biotronik's Orsiro DES

August 28, 2017 -- Biotronik announced data from the BIOFLOW-V randomized trial comparing the company's Orsiro drug-eluting stent (DES) and the Xience DES (Abbott Vascular…

Reva Medical to Market Its Fantom Drug-Eluting Bioresorbable Scaffold as Boston Scientific’s Distribution Option Expires

August 7, 2017 -- Reva Medical, Inc. announced the expiration of Boston Scientific Corporation's exclusive right to negotiate for distribution of Reva Medical's corona…

Five-Year Results Published From the COMPARE II Trial of Terumo's Nobori Biodegradable DES

June 26, 2017 -- The final 5-year report from the COMPARE II trial of an abluminal biodegradable polymer biolimus-A9 -- eluting stent (BP-BES) versus a durable polymer everoli…

Two-Year Results Published From the ISAR-ABSORB Registry of Everolimus-Eluting Bioresorbable Stents in Routine Practice

June 26, 2017 -- Two-year clinical outcomes from the ISAR-ABSORB registry of patients treated in routine practice with everolimus-eluting bioresorbable stent (BRS) implantatio…

Biotronik's Magmaris Resorbable Scaffold Shows Reduced Risk of Thrombosis

May 17, 2017 -- Biotronik announced data demonstrating that the company's Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared with a polymeri…

Micell's MiStent Achieves Primary Endpoint in All-Comers DESSOLVE III Trial

May 16, 2017 -- Micell Technologies, Inc. announced that positive 12-month data from its DESSOLVE III clinical trial were presented by Prof. Robbert J. de Winter, MD, during a…

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.